Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
复制标题
DOI：
10.1016/j.cct.2021.106674
复制
发表时间：
2022-03
影响因子：
2.2
通讯作者：
Fox, Aaron D.
中科院分区：
文献类型：
--
作者：
Perez-Correa, Andres;Abbas, Bilal;Riback, Lindsey;Ghiroli, Megan;Norton, Brianna;Murphy, Sean;Jakubowski, Andrea;Hayes, Benjamin T.;Cunningham, Chinazo O.;Fox, Aaron D.
背景尽管阿片类药物使用障碍（OUD）和过量死亡人数急剧增加，但美国一直无法始终如一地为需要OUD治疗的人提供治疗。注射器服务计划（SSP）可以吸引OUD患者的治疗人群，这些人群具有增加的过量风险。丁丙诺啡治疗是安全有效的，美国法规允许从不同的地点，包括SSP处方。本研究的目的是测试在SSP开始丁丙诺啡治疗。我们假设，提供现场丁丙诺啡治疗启动将提高OUD治疗的参与，而不会降低丁丙诺啡治疗的有效性或safety.MethodsWe将招募250出治疗SSP参与者与OUD在一个大的城市地区。受试者将被随机分配至现场丁丙诺啡治疗启动或加强转诊。在2周内，现场治疗组的参与者将在SSP看到丁丙诺啡提供者两次，每周接受一次药物包，然后他们的护理将转移到社区卫生中心继续治疗。在对照组中，在一周内，参与者将在与干预组相同的社区卫生中心接受丁丙诺啡开始和继续治疗的预约。将通过尿液药物检测、问卷调查和病历审查对参与者进行评估。主要结局将是30天时丁丙诺啡治疗的参与情况。次要结果包括丁丙诺啡转移，阿片类药物的尿液检测，和干预cost-effectiveness.DiscussionOur研究将有助于越来越多的文献上SSP作为一个管道，以OUD治疗。SSP承诺为OUD患者提供所需的护理。
BackgroundDespite dramatic increases in opioid use disorder (OUD) and overdose deaths, the U.S. has been unable to consistently deliver OUD treatment to those who need it. Syringe services programs (SSPs) can engage an out-of-treatment population of people with OUD that has elevated overdose risk. Buprenorphine treatment is safe and effective, and US regulations allow for prescribing from diverse locations, including SSPs. This study's objective is to test buprenorphine treatment initiation at SSPs. We hypothesize that offering onsite buprenorphine treatment initiation will improve OUD treatment engagement without reducing buprenorphine treatment effectiveness or safety.MethodsWe will recruit 250 out-of-treatment SSP participants with OUD in a large urban area. Participants will be randomized to onsite buprenorphine treatment initiation or enhanced referral. Over 2 weeks, participants in the onsite treatment arm will see a buprenorphine provider twice at the SSP, receive weekly medication packs, and then their care will be transferred to a community health center for treatment continuation. In the control arm, within one week, participants will receive an appointment at the same community health center as in the intervention arm for buprenorphine initiation and continuation. Participants will be assessed with urine drug tests, questionnaires, and medical record review. The primary outcome will be engagement in buprenorphine treatment at 30 days. Secondary outcomes include buprenorphine diversion, opioid-free urine drug tests, and intervention cost-effectiveness.DiscussionOur study will contribute to the growing literature on SSPs as a conduit to OUD treatment. SSPs hold promise to deliver needed care to people with OUD.
登录
查看更多内容
丁丙诺啡诱导策略的比较：以患者为中心的家庭归纳与护理标准的基于办公室的归纳。
影响因子：
3.9
作者：
Cunningham CO;Giovanniello A;Li X;Kunins HV;Roose RJ;Sohler NL
通讯作者：
Sohler NL
影响因子：
158.5
作者：
Fiellin, David A.;Pantalon, Michael V.;Schottenfeld, Richard S.
通讯作者：
Schottenfeld, Richard S.
影响因子：
3.3
作者：
Heller, D;McCoy, K;Cunningham, C
通讯作者：
Cunningham, C
影响因子：
3.9
作者：
Baxter, Jeffrey D.;Clark, Robin E.;Hashemi, Lobat
通讯作者：
Hashemi, Lobat
DOI：
10.1186/s13011-017-0107-4
发表时间：
2017-05-16
期刊：
Substance abuse treatment, prevention, and policy
影响因子：
--
作者：
Chandler R;Gordon MS;Kruszka B;Strand LN;Altice FL;Beckwith CG;Biggs ML;Cunningham W;Chris Delaney JA;Flynn PM;Golin CE;Knight K;Kral AH;Kuo I;Lorvick J;Nance RM;Ouellet LJ;Rich JD;Sacks S;Seal D;Spaulding A;Springer SA;Taxman F;Wohl D;Young JD;Young R;Crane HM
通讯作者：
Crane HM